/ Aurobindo Pharma Gains As USFDA Nods For Sevelamer Carbonate Oral Suspension ~ Ways2Capital|Stock Tips|Stock Market Tips|Intraday Stock Tips|Stock Trading Tips|NSE BSE Tips

Thursday, 15 June 2017

Aurobindo Pharma has received final approval from the US Food & Drug Administration (U.S FDA) to manufacture Sevelamer Carbonate Oral suspension, 0.8 gm and 2.4 gm, the company informed the bourses on Thursday.

Sevelamer Carbonate oral suspension is prescribed for the control of serum phosphorus in patients with chronic kidney disease (CKD).

Meanwhile, the stock was trading higher by 6.1% at Rs 638.55 per share at 1128 hours IST on BSE. It hit a high of Rs 640.80 and a low of Rs 600.75 so far during the day. The stock has underperformed BSE Sensex and BSE Healthcare index over a period of one year.

Aurobindo Pharma Limited is engaged in producing oral and injectable generic formulations and active pharmaceutical ingredients (APIs).

or Quick Trial – 8962000225 ✔ 
or mail us here: info@ways2capital.com
or visit http://www.ways2capital.com
✆ - 0731-6626222 | Toll Free - 1800-3010-2007 ✔ 
Give a Missed Call for Free Trial - 09699997717 ✔